Solid Biosciences Inc. Logo

Solid Biosciences Inc.

Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.

SLDB | US

Overview

Corporate Details

ISIN(s):
US83422E2046
LEI:
Country:
United States of America
Address:
500 RUTHERFORD AVENUE, 2129 CHARLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Solid Biosciences is a precision genetic medicine company dedicated to advancing a diverse portfolio of gene therapy candidates. The company focuses on treating rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia (CPVT), and various cardiomyopathies. In addition to its therapeutic pipeline, Solid Biosciences develops innovative enabling technologies, such as libraries of genetic regulators, to improve gene therapy delivery across the industry. Founded by individuals directly impacted by Duchenne, the company maintains a patient-focused mission to improve the lives of people living with devastating rare genetic diseases through scientific and technological expertise.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Solid Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Solid Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Solid Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America
GILD
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom
GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea
204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan
2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary
GWPH
Gossamer Bio, Inc. Logo
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
United States of America
GOSS
Grace Therapeutics, Inc. Logo
Develops improved drugs for rare neurological diseases using novel drug delivery technologies.
United States of America
GRCE
A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.
South Korea
005250
GREEN CROSS WellBeing Corporation Logo
Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.
South Korea
234690

Talk to a Data Expert

Have a question? We'll get back to you promptly.